Literature DB >> 17676930

Phosphorylation-dependent sumoylation of estrogen-related receptor alpha1.

Elizabeth H Vu1, Richard J Kraus, Janet E Mertz.   

Abstract

We previously showed that estrogen-related receptor alpha1 (ERRalpha1) can compete with estrogen receptor alpha (ERalpha) for binding to estrogen response elements (EREs), repressing transcription in the mammary carcinoma cell line MCF-7. Given that ERRalpha1 can function in the absence of ligands and exists as a phosphoprotein in vivo, we wished to determine sites of phosphorylation involved in regulating its transcriptional activity. Using a combination of electrophoretic mobility shift analysis, phospho-specific fluorescent dye staining, and site-directed mutagenesis, we identified two novel in vivo sites of phosphorylation in the A/B ligand-independent activation domain of ERRalpha1 at Ser19 and Ser22. Inhibition of phosphorylation at amino acid residue 22 did not have a significant effect on ERRalpha1's transcriptional activity. However, mutation of amino acid residue 19 from serine to alanine enhanced two-fold ERRalpha1's response to the coactivator GRIP-1. We also identified two sites of sumoylation at Lys14 and Lys403. We found that inhibition of sumoylation at Lys14 could enhance five-fold ERRalpha1's response to coactivator GRIP-1. Furthermore, phosphorylation of Ser19 enhanced the sumoylation at Lys14. Taken together, we conclude that phosphorylation at Ser19 and sumoylation at Lys14 within the A/B domain play roles in regulating ERRalpha1's transcriptional activities via affecting its response to coactivators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17676930     DOI: 10.1021/bi700316g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

Review 1.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

2.  Production and characterization of monoclonal antibodies to estrogen-related receptor alpha (ERRα) and use in immunoaffinity chromatography.

Authors:  Amanda M Esch; Nancy E Thompson; Jennifer A Lamberski; Janet E Mertz; Richard R Burgess
Journal:  Protein Expr Purif       Date:  2012-05-04       Impact factor: 1.650

Review 3.  The Roles of SUMO in Metabolic Regulation.

Authors:  Elena Kamynina; Patrick J Stover
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

4.  A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR.

Authors:  Stéphanie Bilodeau; Véronique Caron; Jonathan Gagnon; Alexandre Kuftedjian; André Tremblay
Journal:  J Mol Cell Biol       Date:  2017-06-01       Impact factor: 6.216

Review 5.  The estrogen-related receptors (ERRs): potential targets against bone loss.

Authors:  Ling Zhang; Jiemin Wong; Jean-Marc Vanacker
Journal:  Cell Mol Life Sci       Date:  2016-08-11       Impact factor: 9.261

6.  The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.

Authors:  J L Fiori; M Sanghvi; M P O'Connell; S M Krzysik-Walker; R Moaddel; M Bernier
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 7.  Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Authors:  Rebecca B Riggins; Mary M Mazzotta; Omar Z Maniya; Robert Clarke
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

8.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18

9.  The biarylpyrazole compound AM251 alters mitochondrial physiology via proteolytic degradation of ERRα.

Authors:  Susan M Krzysik-Walker; Isabel González-Mariscal; Morten Scheibye-Knudsen; Fred E Indig; Michel Bernier
Journal:  Mol Pharmacol       Date:  2012-10-12       Impact factor: 4.436

10.  cAMP enhances estrogen-related receptor alpha (ERRalpha) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2).

Authors:  Dongyuan Liu; Houda Benlhabib; Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2009-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.